Clinical Trial

A Study to Evaluate ALN-4285 in Adult Healthy Volunteers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers * characterize the single-dose pharmacokinetics (PK) of ALN-4285
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-12-10; most recent amendment 2026-07-13.
Status change: Not Yet Recruiting → Recruiting 2026-02-26
Trial Details
NCT Number NCT07295717
Lead Sponsor Alnylam Pharmaceuticals
Conditions Healthy Volunteers
Enrollment 76 participants
Start Date 2025-12-12
Primary Completion 2026-12-29 (estimated)
Study Completion 2027-03-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-12